The Problematical Dr. Huang Hongyun

(Page 7 of 7)

  • January 2005
  • By Horace Freeland Judson

Deadly Decisions
Despite the defects in Huang's work, no definitive judgment is yet possible. Wise Young is a cautious advocate. He notes, "There are really no randomized clinical trials for any of the current neurosurgical procedures." Regarding Huang's work, "The big debate right now is, What is the level of evidence that's necessary and sufficient to take something to clinical trial?" Meanwhile, though, when dealing with spinal-­cord patients and their families, "My official recommendation is that they should wait. Many of them ignore me; they go on ahead to do it anyway." Mary Bunge and her colleagues at the Miami Project find Huang's claims frustrating. "Presently, Dr. Huang's project by research standards in the United States is not a clinical trial but is a clinical treatment series. The treatment series does not meet the design standards for a clinical trial that would allow for definitive results to be obtained." Yet they call for "independent and impartial assessment of the risks and benefits of this cell therapy." Meanwhile, though, "Miami Proj­ect faculty do not endorse this pro­cedure and at this time would not advise individuals to undergo this surgical transplantation strategy. While some people with SCI will view these current experimental procedures abroad as their only hope, by participating they may be putting themselves in harm's way."

The science of Dr. Huang Hongyun raises to our awareness this deep tension over standards of evidence and the ethics of clinical practice.

I saw Huang the afternoon of October 20, 2004. A correspondent from the Mobile, AL, Register, Karen Tolkkinen, was also in Beijing, Huang said; he was to treat several Americans with ALS that week, and one was from Alabama. That evening, he operated on Ronnie Abdinoor, a 47-year-old from New Hampshire. On October 29, Tolkkinen reported in the Register that Abdinoor had died.

Print

Related Articles

Horace Freeland Judson, 1931-2011

Author of The Eighth Day of Creation and a Technology Review contributor dies.

Cell Type Counts in Spinal Therapy

Rats regain motor skills with one kind of cell transplant, get nerve pain with another.

Regenerating Nerves

A polymer studded with chemicals that resemble a common neurotransmitter can stimulate the growth of neurons.

Close Comments

To comment, please sign in or register

Forgot my password

brainandspinalcord

9 Comments

  • 1272 Days Ago
  • 08/21/2008

It's heartbreaking to know that these people are suffering even more because these doctors give them false hope only to use them as guinea pigs. The lack of control and responsibility is very disturbing. It's not surprising that people suffering from a spinal cord injury grab whatever chance they can to regain function, but it is surprising that the doctors are acting in such an unethical manner.

Reply

Advertisement

MAGAZINE

Can We Build Tomorrow's Breakthroughs?

Manufacturing in the United States is in trouble. That's bad news not just for the country's economy but for the future of innovation.

Videos

Meet 2011 TR35 Winner Jesse Robbins

More

Advertisement

Technology Review Lists

TR50

Our list of the 50 most innovative companies, including the following:

Silver Spring Networks

Akamai

Square

Twitter

More

Advertisement
Advertisement